ArticleBiomicrofluidics2015
Pulmonary monoclonal antibody delivery via a portable microfluidic nebulization platform.
Article in Biomicrofluidics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- A novel therapeutic outlook: Classification, applications and challenges of inhalable micron/nanoparticle drug delivery systems in lung cancer (Review).International journal of oncology · 2024Pooled it
- Preferential apical infection and spread of human metapneumovirus highlights the importance of inhaled delivery of neutralizing monoclonal antibody to treat established infections.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Inhaled "Muco-Trapping" Monoclonal Antibody Effectively Treats Established Respiratory Syncytial Virus (RSV) Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Laminar Fluid Ejection for Olfactory Drug Delivery: A Proof of Concept Study.IEEE journal of translational engineering in health and medicine · 2024Article
- RNA Nanomedicine: Delivery Strategies and Applications.The AAPS journal · 2023Review
- Engineering Lipid Nanoparticles for Enhanced Intracellular Delivery of mRNA through Inhalation.ACS nano · 2022Article
- Integrating an aerosolized drug delivery device with conventional static cultures and a dynamic airway barrier microphysiological system.Biomicrofluidics · 2022Article
- Recent advances in acoustic microfluidics and its exemplary applications.Biomicrofluidics · 2022Review
- Cellular Immunotherapy and the Lung.Vaccines · 2021Review
- Inhalation delivery technology for genome-editing of respiratory diseases.Advanced drug delivery reviews · 2021Review
- Prospects of Inhaled Phage Therapy for Combatting Pulmonary Infections.Frontiers in cellular and infection microbiology · 2021Review
- An experimental study of respiratory aerosol transport in phantom lung bronchioles.Physics of fluids (Woodbury, N.Y. : 1994) · 2020Article
- Airway Delivery of Anti-influenza Monoclonal Antibodies Results in Enhanced Antiviral Activities and Enables Broad-Coverage Combination Therapies.Journal of virology · 2020Article
- Future Trends in Nebulized Therapies for Pulmonary Disease.Journal of personalized medicine · 2020Review
- High Frequency Sonoprocessing: A New Field of Cavitation-Free Acoustic Materials Synthesis, Processing, and Manipulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Review
- Pulmonary Deposition of Radionucleotide-Labeled Palivizumab: Proof-of-Concept Study.Frontiers in pharmacology · 2020Article
- Developing inhaled protein therapeutics for lung diseases.Molecular biomedicine · 2020Review
- Acoustofluidic methods in cell analysis.Trends in analytical chemistry : TRAC · 2019Article
- Aerosol delivery into small anatomical airway model through spontaneous engineered breathing.Biomicrofluidics · 2019Article
- Topical application of nebulized human IgG, IgA and IgAM in the lungs of rats and non-human primates.Respiratory research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nebulizers have considerable advantages over conventional inhalers for pulmonary drug administration, particularly because they do not require coordinated breath actuation to generate and deliver the aerosols. Nevertheless, besides being less amenable to miniaturization and hence portability, some nebulizers are prone to denature macromolecular drugs due to the large forces generated during aerosolization. Here, we demonstrate a novel portable acoustomicrofluidic device capable of nebulizing epidermal growth factor receptor (EGFR) monoclonal antibodies into a fine aerosol mist with a mass median aerodynamic diameter of approximately 1.1 μm, optimal for deep lung deposition via inhalation. The nebulized monoclonal antibodies were tested for their stability, immunoactivity, and pharmacological properties, which confirmed that nebulization did not cause significant degradation of the antibody. In particular, flow cytometry demonstrated that the antigen binding capability of the antibody is retained and able to reduce phosphorylation in cells overexpressing the EGFR, indicating that the aerosols generated by the device were loaded with stable and active monoclonal antibodies. The delivery of antibodies via inhalation, particularly for the treatment of lung cancer, is thus expected to enhance the efficacy of this protein therapeutic by increasing the local concentration where they are needed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.